The evolution of cancer treatment is experiencing the emergence of immune checkpoint blockade as a promising strategy with distinct response patterns and challenges. Medical imaging plays a pivotal role in evaluating responses to immunotherapy and monitoring immune-related adverse events, challenging… Read More
Overview: Imaging Endpoints (IE) has established a strong reputation for quality through a perfect inspection record and remarkable marketing authorization success rate and is expanding its quality leadership by integrating the new standards of ICH E6 (R3) into IE’s Quality… Read More
On Tuesday, 23 April 2024, the U.S. FDA granted accelerated approval to Day One Biopharmaceuticals for tovorafenib, the first targeted therapy for relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG). As explained in Day One’s press release, “pLGG is the… Read More
January 2024 – Imaging Endpoints (IE) is a global leader specializing in comprehensive imaging services for clinical trials. Our profound expertise includes analysis of CT, MRI, and PET/SPECT molecular imaging, particularly in the context of gynecologic malignancies, including cervical cancer.… Read More
September is a significant month for many reasons, but in the medical community, it stands out as Childhood Cancer Awareness Month. This month, we spotlight the pressing global health challenge of childhood cancer, which remains one of the leading causes… Read More
Featured Webinar:
Radiologic Analysis of COVID-19 Infection
June 23, 2020
